Clinical Trial Update: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma [Phase 3]

View source ↗

Summary

Clinical Trial Update describing a Phase 3 study comparing Zanubrutinib plus anti-CD20 therapy versus Lenalidomide plus Rituximab in relapsed/refractory follicu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: BeiGene | Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Status: RECRUITING